drugset / Trial / NCT07063407
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Timeline
- Start
- 2025-07-31
- Primary completion
- 2026-04-30
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | HS-20093 | Other / unclassified | — | Intravenous |